Company expects Phase 3 AURORA trial data in myasthenia gravis in 1Q27
Cartesian expects Phase 1 in vivo MG trial with WestGene to initiate in 2H26, data in 1H27
Company anticipates current cash resources will support operations into 2028
Overview
US cell therapy developer's Q2 net income was nearly flat yr/yr at $15.8 mln
Operating expenses rose yr/yr, mainly due to increased Phase 3 AURORA trial costs
Company secured up to $150 mln in non-dilutive financing, extending cash runway into 2028
Result Drivers
R&D SPENDING - Higher research and development expenses were mainly due to increased costs for the ongoing Phase 3 AURORA trial
PIPELINE EXPANSION - New strategic partnership with WestGene aimed at accelerating development of in vivo CAR-T platform and expanding pipeline
CASH RUNWAY EXTENSION - Non-dilutive financing secured, extending cash runway into 2028 and supporting investment in clinical and precommercial activities
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cartesian Therapeutics, Inc. is $39.00, about 367.1% above its August 5 closing price of $8.35
RNAC•
